Does OROS*-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder

Current Medical Research and Opinion

Volumn 22, Issue 12, 2006, Pages 2557-2566

  Fallu, Angelo ^a   Richard, Caroline ^a   Prinzo, Rosanna ^b   Binder, Carin ^b  

^a Clinique Woodward   (Canada)

^b Janssen Ortho Inc   (Canada)

Author keywords

Adult attention deficit hyperactivity disorder; Effectiveness; Executive function; OROS methylphenidate; Safety

Indexed keywords

METHYLPHENIDATE; OROS; UNCLASSIFIED DRUG;

ADULT; AGITATION; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSED MOOD; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; FEVER; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; MALE; MIGRAINE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHYSICAL EXAMINATION; PILOT STUDY; PULSE RATE; SCORING SYSTEM; SIDE EFFECT; SINUSITIS; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; VITAL SIGN; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION; COGNITION DISORDERS; DELAYED-ACTION PREPARATIONS; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; OSMOSIS; PATIENT SATISFACTION; PILOT PROJECTS; PSYCHOLOGICAL TESTS; TREATMENT OUTCOME;

EID: 33846006876     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X154132     Document Type: Article

References (39)

1. American Academy of Pediatrics, Committee on Quality Improvement and Subcommittee on Attention-Deficit/Hyperactivity Disorder. Clinical Practice Guideline, Diagnosis and evaluation of the child with attention-deficit/ hyperactivity disorder. Pediatrics 2000;105:1158-70
2. Adler LA, Chua HC. Management of ADHD in adults. J Clin Psychiatry 2002;63(Suppl 12):29-35
3. Wender PH, Wolf LE, Wasserstein J. Adults with ADHD. An overview. Ann N Y Acad Sci 2001;931:1-16
4. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-23
5. Lamberg L. ADHD often undiagnosed in adults: appropriate treatment may benefit work, family, social life. JAMA 2003;290:1565-7
6. Seidman LJ. Neuropsychological functioning in people with ADHD across the lifespan. Clin Psychol Rev 2006;26:466-85
7. Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004;24:24-9
8. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS-methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006;59:829-35
9. Biederman J, Mick E, Spencer T, et al. An open trial of OROS-methylphenidate in adults with late-onset ADHD. CNS Spectr 2006;11:390-6
10. Barkely RA. Behavioural inhibition, sustained attention and executive function: constructing a unified theory of ADHD. Psychol Bull 1997;121:65-94
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision, Washington DA, The American Psychiatric Association, 2000
12. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), version 2. New York: New York State Psychiatric Institute, Biometrics Research, 1994
13. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993;150:885-90
14. Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales (CAARS): Technical Manual. New York: Multi-Health Systems, 1999
15. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
16. Golden CJ, Freshwater SM. The Stroop Color and Word Test. Manual for Clinical and Experimental Uses. Wood Dale, IL: Stoelting, 2002
17. Wechsler D. Échelle d'intelligence de Wechsler pour adultes - Troisième édition. Version pour francophones du Canada. Manuel d'administration, Édition de recherche. The Psychological Corporation, 2004
18. Gladsjo JA, Schuman CC, Evans JD, et al. Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment 1999;6:147-78
19. Sheehan DV, Sajatovic M, Ramirez LF. Sheehan Disability Scale. Rating Scales in Mental Health. 2nd edn. Hudson, OH: Lexi-Comp, 2003:41-2
20. National Institutes of Mental Health (NIMH). CGI (Clinical Global Impression Scale) - NIMH. Psychopharmacol Bull 1985;21:839-43
21. Likert R. A technique for the measurement of attitudes. Arch Psychology 1932;140:52
22. Steele M, Weiss M, Swanson J, et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in ADHD. Can J Clin Pharmacol 2006;13:e50-62
23. Murphy K, Barkley RA. Attention deficit hyperactivity disorder in adults: comorbidities and adaptive impairments. Compr Psychiatry 1996;37:393-401
24. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63(Suppl 12):10-15
25. Biederman J, Faraone SV, Monuteaux MC, et al. Gender effects on attention-deficit/hyperactivity disorder in adults, revisited. Biol Psychiatry 2004;55:692-700
26. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27:187-201
27. Schoechlin C, Engel R. Neuropsychological performance in adult attention-deficit hyperactivity disorder: meta-analysis of empirical data. Arch Clin Neuropsychol 2005;20:727-44
28. Kessler RC, Adler L, Ames M, et al. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med 2005;47:565-72
29. Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resourc Alloc 2005;3:5
30. Barkley RA, Fischer M, Smallish L. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 2006;45:192-202
31. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with ADHD. Biol Psychiatry 2005;57:456-63
32. Arnsten A, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct 2005;1:2
33. Bekker E, Overtoom C, Kooij JJ, et al. Disentangling deficits in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2005;62:1129-36
34. Mehta MA, Goodyer MI, Sahakian BJ. Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. J Child Psychol Psychiatry 2004;45:293-305
35. Willcutt E, Doyle A, Nigg JT, et al. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry 2005;57:1336-46
36. Aron A, Dowson JH, Sahakian BJ, et al. Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry, 2003;54:1465-8
37. Turner DC, Blackwell AD, Dowson JH, et al. Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 2004;178:286-95
38. Schweitzer JB, Lee DO, Hanford RB, et al. Effect of methylphenidate on executive functioning in adults with attention-deficit/hyperactivity disorder: normalization of behavior but not related to brain activity. Biol Psychiatry 2004;56:597-606
39. Wilens T, McBurnett K, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2005;44:1015-23